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Cellulitis (also known as erysipelas) is a common infection of
the skin and subcutaneous tissues, and therefore falls within
the domain of dermatologists. Cellulitis, which can often be
recurrent, is among the top 10 reasons for admission to hos-
pital, with patients receiving treatment from many specialties
including emergency care, general practitioners, general medi-
cine, surgery, tissue viability and dermatology.1
In this issue of the BJD, Burian et al.2 examine the prevalence
of cellulitis in patients with chronic oedema. Chronic oedema
is an easily identified clinical sign and leads to the same
pathophysiological effects and appearances as lymphoedema,
which is not so easily distinguished. Tissue fluid is predomi-
nantly drained by the lymphatic system and not by venous
reabsorption as was previously thought.3 This means that all
chronic oedema, i.e. subcutaneous oedema persisting for at
least 3 months, is caused either by an absolute reduction in
lymph transport, as in lymphoedema, or by lymph drainage
being overwhelmed by a fluid (lymph) load, such as that
which occurs with higher venous pressures from heart failure
or venous disease. Therefore, chronic oedema always repre-
sents lymph drainage failure, and as it is easy to identify and
has the same physiological effects, it can be considered a sur-
rogate for lymphoedema.4 As lymph carries antigen related to
infection as well as lymphocytes for an appropriate immune
response, disturbed lymph drainage, whether owing to fluid
load or lymph vessel dysfunction, results in immunodeficiency
as a consequence of the disturbed immune cell trafficking.5
The novel findings from this publication are that one-third
of patients with chronic oedema are likely to develop cellulitis
at some point. The worse the oedema, the more likely celluli-
tis is to occur; the better the oedema, the less likely cellulitis
is to occur. The strengths of this publication are the large
number of patients included for study and the international
collaboration involving nine countries, indicating that chronic
oedema predisposing to cellulitis is a global healthcare burden
– at least in these countries. By targeting healthcare profes-
sionals with an interest in lymphoedema to identify patients,
numbers may have been falsely elevated and more severe cases
included compared with the population at large, but this does
not undermine the value of the results. Unfortunately, data on
recurrent cellulitis were not included and this is likely to be a
common occurrence. As shown previously, cellulitis can be
self-perpetuating with past episodes making future episodes
more likely.6 While prophylactic penicillin has been shown to
be of value in preventing cellulitis,6 this study demonstrates
the importance of controlling the chronic oedema in prevent-
ing cellulitis, a finding recently confirmed by the use of com-
pression garments to prevent cellulitis.7 So often in healthcare,
patients are treated for the acute episode of cellulitis and dis-
charged without sufficient consideration being given to treat-
ment of the risk factors, such as chronic oedema, skin disease
and wounds. Dermatologists are well placed to manage such
conditions and therefore should be more involved in cellulitis
care. The Norwich model has shown the value of dermatolog-
ical input for cellulitis,8 particularly as red legs do not always
mean cellulitis and mismanagement frequently occurs.9
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